Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 52, 102987
Abstract
No abstract availableKeywords
Funding Information
- AP Møller and Chastine McKinney Møller Foundation
- Danish Multiple Sclerosis Society
- Strategic Research Council
This publication has 35 references indexed in Scilit:
- B cells undergo unique compartmentalized redistribution in multiple sclerosisJournal of Autoimmunity, 2011
- HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2010
- Key developmental transitions in human germinal center B cells are revealed by differential CD45RB expressionBlood, 2009
- Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosisNeurology, 2008
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- Natalizumab effects on immune cell responses in multiple sclerosisAnnals of Neurology, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosisBrain, 2005
- Molecular pathways in bone marrow homing: dominant role of α4β1 over β2-integrins and selectinsBlood, 2001
- Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways.Journal of Experimental Medicine, 1991